Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 5Not yet recruiting 5Completed 5Withdrawn 3Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Platinum-Resistant Lung Small Cell Carcinoma 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × PM 01183 × Clear all
NCT05099666 2026-04-13

Lurbinectedin + Doxorubicin In Leiomyosarcoma

Massachusetts General Hospital

Phase 1/2 Active not recruiting
62 enrolled
Sarcoma

Sarcoma

NCT04607954 2026-03-31

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Mayo Clinic

Phase 2 Active not recruiting
29 enrolled

Platinum-Resistant Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡